Read More

Alaunos Therapeutics Highlights Strategic Priorities And Anticipated Portfolio Milestones For 2023; Alaunos Ended Q4 2022 With Unaudited Cash And Cash Equivalents Of ~$39.1M And Restricted Cash Of ~$13.9M

Announcing addition of two new TCRs to the library, estimated to double the addressable market; plans to further expand TCR library using hunTR® TCR discovery platform   Increasing patient enrollment to

TCRT

Read More

US Stock Futures Down Ahead Of Fed Speakers, Economic Data

Pre-open movers U.S. stock futures traded lower in early pre-market trade on Wednesday after closing mostly lower on Tuesday. The S&P 500 index dropped deeper into a bear market after hitting a fresh 2022 low. The S&P 500 is now down 24.3% from its record level in January, while the Dow is now 21.2% below its record high.

AGCO